U
MDCO

UBS’s Medicines Co MDCO Stock Holding History

UBS’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100
Closed -$3K – 10975
2014
Q2 		$3K Buy
+100
New +$2.67K ﹤0.01% 9896
2013
Q4 		– Sell
-1,400
Closed -$47K – 10955
2013
Q3 		$47K Sell
1,400
-1,600
-53% -$51K ﹤0.01% 6955
2013
Q2 		$92K Buy
+3,000
New +$100K ﹤0.01% 6015

Other funds holding MDCO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

UBS's MDCO Position: Q3 2014 in Review

UBS increased its Medicines Co (MDCO) stake by 29% in Q3 2014, buying an estimated $30.4K and bringing the position to 5,304 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #5780.

UBS first reported a position in MDCO in Q2 2013 and has held it in 6 quarters since. The position peaked at $4.3M in Q2 2013. 152 funds tracked by Wall St. Rank hold MDCO as of Q3 2014.

  • UBS held 5,304 shares of Medicines Co worth $119K as of Q3 2014.
  • UBS bought 1,196 Medicines Co shares in Q3 2014, an estimated $30.4K.
  • Medicines Co made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5780 holding.
  • UBS first reported a position in Medicines Co in Q2 2013 and has held it in 6 quarters since.
  • UBS's Medicines Co position peaked at $4.3M in Q2 2013.
  • 152 funds tracked by Wall St. Rank held Medicines Co as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.